You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

Investigational Drug Information for CC-220


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug CC-220?

CC-220 is an investigational drug.

There have been 26 clinical trials for CC-220. The most recent clinical trial was a Phase 2 trial, which was initiated on November 12th 2021.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and Bristol-Myers Squibb.

There are twenty-nine US patents protecting this investigational drug and two hundred and eighty international patents.

Recent Clinical Trials for CC-220
TitleSponsorPhase
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaBristol-Myers SquibbPhase 3
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult ParticipantsCelgenePhase 1
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult ParticipantsBristol-Myers SquibbPhase 1

See all CC-220 clinical trials

Clinical Trial Summary for CC-220

Top disease conditions for CC-220
Top clinical trial sponsors for CC-220

See all CC-220 clinical trials

US Patents for CC-220

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-220 ⤷  Try a Trial Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies Celgene Corporation (Summit, NJ) ⤷  Try a Trial
CC-220 ⤷  Try a Trial Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin- e-2,6-dione Celgene Corporation (Summit, NJ) ⤷  Try a Trial
CC-220 ⤷  Try a Trial Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast Celgene Corporation (Summit, NJ) ⤷  Try a Trial
CC-220 ⤷  Try a Trial Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same Celgene Corporation (Summit, NJ) ⤷  Try a Trial
CC-220 ⤷  Try a Trial 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-- dione for the treatment of systemic lupus erythematosus Celgene Corporation (Summit, NJ) ⤷  Try a Trial
CC-220 ⤷  Try a Trial Apremilast for the treatment of a liver disease or a liver function abnormality Celgene Corporation (Summit, NJ) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-220

Drugname Country Document Number Estimated Expiration Related US Patent
CC-220 Australia AU2015305449 2034-08-22 ⤷  Try a Trial
CC-220 Australia AU2021209158 2034-08-22 ⤷  Try a Trial
CC-220 Brazil BR112017003620 2034-08-22 ⤷  Try a Trial
CC-220 Canada CA2958867 2034-08-22 ⤷  Try a Trial
CC-220 Chile CL2017000416 2034-08-22 ⤷  Try a Trial
CC-220 China CN107073115 2034-08-22 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.